Drugs Made In America Acquisition Corp. Rights

DMAAR•United States

Financial Services United States Financial Conglomerates

Need professional-grade analysis? Visit stockanalysis.com

$0.09

+10.86%

End of day

Market Cap

$1.08M

P/E Ratio

N/A

Employees

N/A

Dividend Yield

N/A

Price Chart

Risk-Adjusted Performance

Ratio	1W	1M	3M	6M	1Y	5Y	Score
Sortino	—	—	-0.76	-0.79	—	—	-0.78
Calmar	—	—	-1.22	-0.97	—	—	-1.08
Sharpe	—	—	-0.46	-0.51	—	—	-0.49
Omega	—	3.61	0.92	0.91	—	—	1.51
Martin	—	—	-2.15	-1.93	—	—	-2.03
Ulcer	—	5.96	38.94	39.42	—	—	31.82

Drugs Made In America Acquisition Corp. Rights (DMAAR) Price Performance

Drugs Made In America Acquisition Corp. Rights (DMAAR) trades on United States in USD. The company is classified in the Financial Services sector under the Financial Conglomerates industry. The stock currently trades at $0.09, up 10.86% from the previous close.

Over the past year, DMAAR has traded between a low of $0.04 and a high of $0.23. The stock has lost 26.0% over this period. It is currently 61.4% below its 52-week high.

Drugs Made In America Acquisition Corp. Rights has a market capitalization of $1.08M.

About Drugs Made In America Acquisition Corp. Rights

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.

Company Info

Sector: Financial Services
Industry: Financial Conglomerates
Exchange: United States
Currency: USD
Country: United States

Financial Metrics

Revenue (TTM): N/A
EBITDA: N/A
Profit Margin: N/A
EPS (TTM): N/A
Book Value: -0.22

Technical Indicators

52 Week High: $0.24
52 Week Low: $0.04
50 Day MA: $0.10
200 Day MA: N/A
Beta: N/A

Valuation

Trailing P/E: N/A
Forward P/E: N/A
Price/Sales: N/A
Price/Book: N/A
Enterprise Value: $1.08M